Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.

Alex Zhavoronkov, Fedor Galkin, Shan Chen, Feng Ren, Alex Aliper, Mikhail Durymanov, Denis Sidorenko, Hui Cui, Jing-Dong J Han, Hao Xu, Xiaodong Liu, Zuojun Xu, Christoph Kuppe, M Austin Argentieri, Kejun Ying, Ludger J E Goeminne, Mahdi Moqri, Alexander Tyshkovskiy, Vadim N Gladyshev

Insilico Medicine AI Limited, Abu Dhabi, United Arab Emirates. [email protected] Medicine AI Limited, Abu Dhabi, United Arab Emirates. [email protected]. · pubmed

Paper

Abstract

Drugs for aging-related diseases may modulate aging itself, but standard clinical trial designs cannot detect such effects. Aging clocks could close this gap, but epigenetic models often yield inconsistent, hard-to-interpret results. In contrast, proteomic clocks, by tracking the immediate effectors of biological change, may excel in providing aging biomarkers or mechanistic insight. Here we compare six proteomic clocks (ProtAge, OrganAge

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper demonstrates that proteomic aging clocks can provide consistent and interpretable biomarkers for assessing geroprotective effects in clinical trials. This is relevant because it addresses the critical methodological gap in aging research regarding how to detect and validate interventions that slow biological aging, rather than just treating specific age-related symptoms.

Author of this paper? Send a correction.